PDCD1 and esophageal squamous cell carcinoma: The baseline characteristics of the Japanese patient subgroup in RATIONALE-302 were comparable with those of the Japanese patient subgroups in the previously reported PD-1 inhibitor trials in this setting [10, 11], supporting the relevance and applicability of our findings to Japanese patients with advanced or metastatic ESCC.